References
- Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73:1–8.
- Furneri G, Mantovani LG, Belisari A, et al. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin Exp Rheumatol. 2012;30:S72–84.
- Brooks PM. The burden of musculoskeletal disease – a global perspective. Clin Rheumatol. 2006;25:778–781.
- Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492–509.
- Singh JA, Saag KG, Bridges SL, et al. American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol (Hoboken, N.J.). 2015;68:1–26.
- Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M et al. Eular recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017; 76: 960–977.
- Aletaha D, Landewe R, Karonitsch T, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum. 2008;59:1371–1377.
- Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:516–528.
- Orlewska E, Ancuta I, Anic B, et al. Access to biologic treatment for rheumatoid arthritis in central and Eastern European (CEE) countries. Med Sci Monit. 2011;17:SR1–13.
- Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73:198–206.
- Putrik P, Ramiro S, Kvien TK, et al. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country’s wealth? Ann Rheum Dis. 2014;73:2010–2021.
- Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford). 2002;41:1367–1374.
- Humphreys JH, Verstappen SMM, Hyrich KL, et al. The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. Ann Rheum Dis. 2013;72:1315–1320.
- Sokka T, Kautiainen H, Toloza S, et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis. 2007;66:1491–1496.
- Kavanaugh A, Klareskog L, van der Heijde D, et al. Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate. Ann Rheum Dis. 2008;67:1444–1447.
- Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANIBO registry. Arthritis Rheum. 2010;62:22–32.
- World Bank. World development indicators. Population. [Internet]. 2016. Available from: http://data.worldbank.org/indicator/SP.POP.TOTL
- World Bank. Health expenditure, public (% of GDP). [Internet] 2013. Available from:http://data.worldbank.org/indicator/SH.XPD.PUBL.ZS
- World Bank. GDP per capita, PPP (current international $). [Internet] 2015. Available from: ttp://data.worldbank.org/indicator/NY.GDP.PCAP.PP.CD?order
- Carmona L, Cross M, Williams B, et al. Rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2010;24:733–745.
- European Medicines Agency (EMA). European public assessment reports [Internet]. [ cited 2017 Jun 6]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=&alreadyLoaded=true&isNewQuery=true&status=Authorised&keyword=Enter+keywords&searchType=name&taxonomyPath=Diseases.Musculoskeletal+D
- Kobelt G, Lekander I, Santesson Nicolae Y. Access to innovative treatments for rheumatoid arthritis in New Zealand. A comparison with Australia and the UK. [Internet] 2010. Available from : https://www.arthritis.org.nz/wp-content/uploads/2014/05/ACCESS-TO-INNOVATIVE-TREATMENTS-RA-FINAL.pdf
- World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs) [Internet]. 2009. Available from: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf
- Gulácsi L, Brodszky V, Baji P, et al. Biosimilars for the management of rheumatoid arthritis: economic considerations. Expert Rev Clin Immunol. 2015;11(Suppl 1):S43–52.